Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse 01:30:02 17/07/2024 am IST Pre-market 05:41:00 pm
151 USD +1.19% Intraday chart for Johnson & Johnson 151.4 +0.24%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Genmab, J&J Log Higher Q2 Sales for Blood Cancer Drug Darzalex MT
Stock Futures Decline as Traders Await More Earnings; Asia, Europe Churn MT
Johnson & Johnson Maintains Quarterly Dividend at $1.24 per Share, Payable Sept. 10 to Shareholders of Record on Aug. 27 MT
J&J: Quarterly adjusted EPS up 10.2 CF
Johnson & Johnson Q2 Adjusted Earnings, Revenue Rise; Lowers Full-Year Earnings Guidance MT
Johnson & Johnson Announces Quarterly Cash Dividend for Third Quarter of 2024, Payable on September 10, 2024 CI
Earnings Flash (JNJ) JOHNSON & JOHNSON Posts Q2 Revenue $22.45B MT
Earnings Flash (JNJ) JOHNSON & JOHNSON Reports Q2 EPS $2.82 MT
Wall St futures slump after rally as tech stocks slide RE
EU court criticizes Commission over handling of COVID vaccine contracts RE
ORIC Pharmaceuticals, Inc. Enters into Clinical Trial Collaboration and Supply Agreements with Bayer and Janssen Research & Development, LLC CI
EQT Unit Invests in Biotechnology Company Asceneuron MT
Equity Markets Higher After Fed Chair Powell's Comments MT
Equity Markets Rise Intraday After Fed Chair Powell's Comments MT
Stocks Gain Pre-Bell Ahead of Key Earnings; Asia Mixed, Europe Down MT
Brace for a flurry of speeches from Fed officials Our Logo
Certain Common Stock of Kenvue Inc. are subject to a Lock-Up Agreement Ending on 14-JUL-2024. CI
J&J: completes acquisition of Yellow Jersey for $1.25 billion CF
Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeutics MT
Mixed feelings Our Logo
Emergent Biosolutions, Johnson & Johnson Settle Dispute Over COVID-19 Vaccine Manufacturing MT
Indivior shares dive on profit warning, dropping of schizophrenia drug (July 9) RE
Emergent, J&J settle COVID vaccine supply deal dispute RE
Emergent Biosolutions to Get $50 Million from Covid-19 Manufacturing Settlement with Johnson & Johnson Unit DJ
J&J to pay $50 million to Emergent to resolve manufacturing deal for COVID vaccine RE
Chart Johnson & Johnson
More charts
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
151 USD
Average target price
171.5 USD
Spread / Average Target
+13.56%
Consensus
1st Jan change Capi.
-3.66% 36TCr
+61.53% 85TCr
+32.46% 63TCr
+15.06% 32TCr
+9.18% 30TCr
+12.76% 23TCr
+16.37% 23TCr
+15.67% 18TCr
+2.47% 17TCr
+1.74% 13TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. News Johnson & Johnson
  5. Earnings Flash (JNJ) JOHNSON & JOHNSON Posts Q2 Revenue $22.45B